Study: Mydayis Improves Workplace Performance for Adults with ADHD
A randomized, double-blind study found that treatment with SHP465 mixed amphetamine salts (MAS) is correlated with improved problem-solving skills when compared with a placebo.
June 22, 2018
Adults with ADHD commonly struggle to get started on tasks, and to persist through boring or tedious projects. A recent study1 sought to determine if SHP465 mixed amphetamine salts (MAS) could improve those skills at work.
The researchers randomly assigned 86 adults with ADHD to receive doses of SHP465 MAS extended-release, SHP465 MAS immediate-release, or a placebo. SHP465 MAS comprises equal parts dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate monohydrate. Its extended-release formulation is the generic name for the long-acting drug Mydayis.
At the end of three seven-day treatment periods, researchers measured efficacy by studying subjects’ improvement on the common assessment scale the Permanent Product Measure of Performance (PERMP) in a simulated office environment.
“The primary finding of this study is that SHP465 MAS produced significantly greater improvement in Permanent Product Measure of Performance (PERMP) total score than placebo in adults with ADHD in the adult workplace environment,” says lead study author Timothy Wigal, Ph.D.
Adults treated with SHP465 MAS extended-release attempted and correctly answered more problems on the PERMP than those taking the immediate-release formulation or a placebo. The benefits lasted up to 16 hours. The immediate-release out-performed the placebo nominally.
The most common side effects reported were insomnia and loss of appetite.
This research was funded by Shire, the pharmaceutical company that owns Mydayis.
1Wigal, Timothy, et al. “A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design.” Postgraduate Medicine, 18 June 2018. doi: 10.1080/00325481.2018.1481712
